Skip to main content
. 2021 Feb 10;4(2):e2036645. doi: 10.1001/jamanetworkopen.2020.36645

Table 1. Characteristics of Participants at Baseline.

Characteristic No. (%)
Levothyroxine (nā€‰=ā€‰211) Placebo (nā€‰=ā€‰216)
Age, mean (range), y 73.99 (65.37-91.17) 75.04 (65.12-93.40)
Women 118 (56) 121 (56)
Previous medical conditions and clinical descriptors
Atrial fibrillation 28 (13) 23 (11)
Hypertension 102 (48) 98 (46)
Diabetes 34 (16) 26 (12)
Osteoporosis 26 (13) 31 (15)
Current smoking 18 (9) 19 (9)
Dementia 0 0
Excess alcohol consumptiona 2 (1) 3 (1)
Antidepressants medication 16 (8) 10 (5)
Mini-Mental State Examination score, mean (SD) 28.52 (1.39) 28.68 (1.42)
Weight
Mean (range), kg 77.58 (46-150) 76.76 (44-121)
<50 kg 4 (2) 3 (1)
BMI, mean (SD) 27.88 (5.54) 27.60 (4.37)
TSH, mean (SD) [range], mIU/L 6.57 (2.22) [4.60-17.58] 6.55 (2.04) [4.60-17.60]
Free T4, mean (SD) [range], pmol/L 13.69 (1.97) [10.00-20.60] 13.61 (1.86) [9.00-21.90]
GDS-15 score, mean (SD) [range] 1.26 (1.85) [0-9] 0.96 (1.58) [0-12]

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GDS-15, 15-item Geriatric Depression Scale Questionnaire (range, 0-15; higher scores indicate more severe depressive symptoms; minimal clinically important difference, 2 points); TSH, thyroid stimulating hormone; T4, thyroxine.

a

More than 35 units per week for women and more than 50 units per week for men.